

# cefaZOLIN

**BRAND NAME** CEFAZOLIN AFT, ALPHAPHARM, HOSPIRA, JUNO

**DRUG CLASS** Cephalosporin antibiotic

**AVAILABILITY** Vial contain 500 mg, 1 g or 2 g of cefazolin as cefazolin sodium. Each 1 g contains 2.1 mmol of sodium.<sup>1</sup>

**WARNING** Contraindicated in patients with severe immediate (IgE mediated) or severe delayed (T-cell mediated) hypersensitivity to penicillins. Seek specialist advice for patients with non-severe immediate hypersensitivity to penicillins.

**pH** 4.5–6 when reconstituted<sup>1</sup>

**PREPARATION** **For IM use:** reconstitute the 500 mg vial with 2 mL and the 1 g vial with 2.5 mL of water for injections or lidocaine 0.5%. Shake well and warm in the hands to aid dissolution. Final volumes are 2.2 mL and 3 mL and the approximate concentrations are 225 mg/mL and 330 mg/mL respectively.<sup>1</sup> Do not reconstitute the vial with sodium chloride 0.9% as small crystals may form and they may be difficult to see.<sup>2</sup> Solutions reconstituted with lidocaine must not be injected intravenously.

**For IV use:** reconstitute the vial with at least 10 mL of water for injections.<sup>1</sup> If a part-dose is required, use the following table to reconstitute the vial:

Vial size	Volume of water for injections	Concentration
500 mg	4.8 mL	100 mg/mL
1 g	9.5 mL	100 mg/mL
2 g	19 mL	100 mg/mL

**For intracameral use:** must be reconstituted and diluted under aseptic conditions, preferably by pharmacy.

The solution is clear and light yellow.<sup>2</sup>

Powder volume: 500 mg – 0.2 mL, 1 g – 0.5 mL, 2 g – 1 mL.<sup>1,3</sup>

**STABILITY** Vial: store below 25 °C. Protect from light.<sup>1</sup>

Reconstituted solution: stable for 24 hours at 2 to 8 °C.<sup>1</sup> Crystals may form if the solution is refrigerated. Redissolve by shaking the vial and warming in the hands.<sup>1</sup>

Infusion solution: stable for 24 hours below 25 °C.<sup>2</sup>

For CoPAT use: stable for 24 hours at 37 °C.<sup>4</sup> (based on a solution of 72.2 mg/mL in water for injections). Infusion solutions prepared in a sterile production unit are stable for more than 7 days at 2 to 8 °C.<sup>2</sup>

**ADMINISTRATION**

**IM injection** Suitable<sup>1</sup>

**SUBCUT injection** Not recommended

**IV injection** Inject slowly over 3 to 5 minutes.<sup>1</sup> A dose of 2 g can be given over at least 5 minutes.

**IV infusion** Dilute the dose with 50–100 mL of a compatible fluid and infuse over 10 to 60 minutes.<sup>1</sup> Suitable for doses of 2 to 4 g given once or twice daily.<sup>5</sup>

Doses of 6 to 8 g are given as a 24 hour continuous infusion in the community setting.<sup>5</sup>

**IV use for infants and children** Reconstitute to 100 mg/mL or weaker and inject over 3 to 5 minutes. For IV injection in fluid-restricted patients a concentration of 142 mg/mL in water for injections has been used.<sup>6</sup> Or dilute to 20 mg/mL and infuse over 10 to 60 minutes.<sup>7</sup>

**Other** Suitable for intracameral injection during eye surgery. Very low doses are used and special preparation is required.<sup>8</sup>

*continued over the page*

## COMPATIBILITY

- Fluids** Glucose 5%<sup>1</sup>, glucose 10%<sup>1</sup>, glucose in sodium chloride solutions<sup>1</sup>, Hartmann's<sup>1</sup>, Plasma-Lyte 148 via Y-site<sup>9</sup>, Ringer's<sup>1</sup>, sodium chloride 0.9%<sup>1</sup>
- Y-site** Aciclovir<sup>2</sup>, amifostine<sup>2</sup>, anidulafungin<sup>2</sup>, atracurium<sup>2,10</sup>, aztreonam<sup>2,10</sup>, bivalirudin<sup>2</sup>, buprenorphine<sup>10</sup>, calcium gluconate<sup>10</sup>, ciclosporin<sup>10</sup>, clindamycin<sup>10</sup>, dexamethasone<sup>10</sup>, dexmedetomidine<sup>2</sup>, digoxin<sup>10</sup>, esmolol<sup>2,10</sup>, fentanyl<sup>10</sup>, filgrastim<sup>2</sup>, fluconazole<sup>2,10</sup>, foscarnet<sup>2</sup>, furosemide<sup>10</sup>, glyceryl trinitrate<sup>10</sup>, granisetron<sup>2</sup>, heparin sodium<sup>2,8</sup>, hydrocortisone sodium succinate<sup>10</sup>, indomethacin<sup>10</sup>, lidocaine<sup>10</sup>, linezolid<sup>2</sup>, methylprednisolone sodium succinate<sup>10</sup>, metoclopramide<sup>10</sup>, midazolam<sup>2,10</sup>, morphine sulfate<sup>2,10</sup>, nicardipine<sup>2</sup>, noradrenaline (norepinephrine)<sup>10</sup>, palonosetron<sup>2</sup>, pethidine<sup>2</sup>, potassium chloride<sup>10</sup>, ranitidine<sup>10</sup>, remifentanyl<sup>2</sup>, sodium bicarbonate<sup>10</sup>, sodium nitroprusside<sup>10</sup>, suxamethonium<sup>10</sup>, vecuronium<sup>2</sup>, verapamil<sup>10</sup>

## INCOMPATIBILITY

- Fluids** No information
- Drugs** Aminoglycosides: amikacin, gentamicin, tobramycin<sup>1</sup>, ascorbic acid<sup>2</sup>, azathioprine<sup>11</sup>, calcium chloride<sup>11</sup>, caspofungin<sup>2</sup>, cefotaxime<sup>11</sup>, dobutamine<sup>11</sup>, dopamine<sup>11</sup>, erythromycin<sup>11</sup>, ganciclovir<sup>11</sup>, haloperidol lactate<sup>11</sup>, hydralazine<sup>11</sup>, isavuconazole<sup>2</sup>, mivacurium<sup>11</sup>, mycophenolate mofetil<sup>11</sup>, pentamidine<sup>2</sup>, phentolamine<sup>11</sup>, promethazine<sup>2</sup>, protamine<sup>11</sup>, pyridoxine<sup>11</sup>, rocuronium<sup>1</sup>, sodium ascorbate<sup>1</sup>

## REFERENCES

1. Product information. Available from [www.tga.gov.au](http://www.tga.gov.au). Accessed 15/05/2021.
2. McEvoy GK editor. Handbook on injectable drugs. 20th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2018.
3. AFT Quality assurance. Displacement values [email]. North Ryde, NSW: AFT Pharmaceuticals. 30/10/2019.
4. Bing CD, Nowobilski-Vasiliois A. Extended stability for parenteral drugs. 6th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2017.
5. Antibiotic stability and preparation in community-based parenteral antimicrobial therapy [April 2019]. In: eTG complete [internet]. Melbourne: Therapeutic Guidelines Ltd; March 2021.
6. Phelps S, Hagemann TM, Lee KR, Thompson AJ. Pediatric injectable drugs. 11th ed. Bethesda, MD: Am Soc Health-System Pharmacists; 2018.
7. Taketomo C, Hodding J, Kraus D. Pediatric and neonatal dosage handbook. 26th ed. Hudson, OH: Am Pharm Association. Lexicomp; 2019-2020.
8. Surgical prophylaxis for ophthalmic surgery [March 2021]. In: eTG complete [internet]. Melbourne: Therapeutic Guidelines Ltd; March 2021.
9. OneCall Medical Information Service. Y-Site compatibility of intravenous drugs with Plasmalyte 148. Toongabbie, NSW: Baxter; 2015.
10. Trissel LA, Leissing NC. Trissel's Tables of physical compatibility. Lake Forest IL: Multimatrix; 1996.

11.Cefazolin. In: IV index [internet]. Trissel's 2 clinical pharmaceuticals database (parenteral compatibility). Greenwood Village, CO: Truven Health Analytics. Accessed 02/10/2019.